Precision Medicine Market Analysis of Future Growth, Opportunities, Current Scope and Revenue Estimation
Precision
Medicine Market: Year 2022-2027 and its Detail Analysis by Focusing on Top Key
Players
Precision medicine is a growing approach for the treatment of
disease and preventive health. According to MRFR reports, the precision
medicine market will likely hit USD 126.14 billion by the end of 2025, with a
CAGR of 12.48%. The precision medicine
market allows the patient's participation in taking care of personal health and
offers more targeted therapies to the individuals that will propel the
precision medicine market growth in the coming years. The growing prevalence of
numerous genetic diseases is anticipated to boost the growth of the precision
medicine market. The introduction of pharma and biotech industries with big
data healthcare companies is likely to propel precision medicine market growth.
The growth of the precision
medicine market is attributed to many growth drivers like the rise of
data-driven healthcare, increasing incidence rate of cancer, cost-effective
profiling of DNA, companion diagnostic assay, and increasing approval of the
drug. Furthermore, the rising use of 'multi-omics' in research and the
penetration of high-throughput sequencing platforms is also likely to fuel the
market's growth in a forecasted period.
The present rise in the price of drug discovery with the rise in
regulatory needs has boosted the demand for personalized medicines, which is
offering momentum to market growth. However, the increased costs of diagnosis
and rise in concerns regarding data security might impede the market's growth.
Competitive Analysis
The list of prominent leaders in the precision medicine market
includes the companies like CETICS Healthcare Technologies GmbH, Cepheid Inc.,
bioMérieux SA, Almac Group, Ltd., GlaxoSmithKline Plc (GSK), Johnson &
Johnson, Pfizer Inc, Qiagen, Randox Laboratories Ltd, Quest Diagnostics Inc.,
Roche Holding AG-Br, Caris Life Sciences, HealthCore, Inc., Molecular Health
GmbH, and Precision for Medicine, IBM, Intel Corporation, Sanofi Pharma,
BIOBASE GmbH (Subsidiary), Intomics A/S, ASURAGEN, Inc., ABBOTT LABORATORIES,
LABORATORY CORPORATION OF AMERICA HOLDINGS and many others.
Get Sample Report: https://www.marketresearchfuture.com/sample_request/925
Segment Analysis
The global precision medicine market is bifurcated into numerous
segments based on ecosystem players, therapeutics, and submarkets.
Based on sub-markets, the classification
is done as molecular diagnostics, targeted therapeutics, pharmacogenomics or
PGX, companion diagnostics, biomarker-based tests, and many more.
The global precision medicine market segmentation based on therapeutics includes infectious disease, cancer or
oncology, central nervous system, cardiovascular disease or CVD, and others.
The ecosystem players segment includes healthcare IT specialists or big data
companies, clinical laboratories, pharmaceuticals, biotechnology companies, and
diagnostics companies.
Regional Analysis
On the basis of geography, the precision
medicine market is divided into regions like the Middle East, Africa, Europe,
Asia-Pacific, Latin America, and North America. Among all these, the North American
regional market for precision medicines is projected to account for the largest
market share in the forecasted period. The growth of advanced gene mapping
technologies is the major factor boosting the regional market growth. The European region has been recorded as the
second-largest shareholder in the global precision medicine market attributed
to better electronic health care records, drugs, and diagnostics tools. For the
Asia Pacific region, the Singapore precision medicine market is likely to register
substantial growth mainly due to the better healthcare infrastructure and
increased disposable income.
Selvita has confirmed that
its strategic investment has been concluded by acquiring Fidelta. The
transaction completes soon after the very first notice. For a market valuation
of €31.2 million plus standard allowance for total capital and corporate
capital, Selvita bought 100 per cent of the shareholders' equity of Fidelta.
Read Complete Report @ https://www.marketresearchfuture.com/reports/precision-medicine-market-925
Related Reports: U.S. Direct Anterior
Approach Market Research Report –Global Forecast to 2027
Magnetic Resonance
Imaging (MRI) Market Research Report – Forecast to 2027
Endometrial Cancer
Market Research Report – Forecast to 2027
Digital Wound
Measurement Devices Market Research Report – Forecast to 2027
Flow Cytometry Market
Research Report – Forecast to 2027
About US:
Market Research Future
(MRFR) enable customers to unravel the complexity of various industries through
Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research
Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting
Services.
Contact us:
Market Research Future
(part of Wantstats Research and Media Private Limited),
99 Hudson Street,5Th Floor,
New York,
New York 10013
Comments
Post a Comment